| Joel D Brownell, MD | |
|
9300 Valley Childrens Pl, Madera, CA 93638-8761 | |
| (559) 353-6425 | |
| (559) 353-5708 |
| Full Name | Joel D Brownell |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 9300 Valley Childrens Pl, Madera, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083681506 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | A64313 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joel D Brownell, MD 9300 Valley Childrens Pl, Madera, CA 93638-8761 Ph: (559) 353-6425 | Joel D Brownell, MD 9300 Valley Childrens Pl, Madera, CA 93638-8761 Ph: (559) 353-6425 |
News Archive
The Results for Development Institute's Center for Global Health R&D Policy Assessment blog features an interview with Judit Rius Sanjuan, U.S. manager of the Access Campaign of Medecins Sans Frontieres (MSF), who discusses the final report of the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination.
USA Today asks what the additional $1 trillion cost of a health care overhaul (over 10 years) will actually buy. "Although the eye-popping price tag would help boost insurance coverage to 95% or more of the public, it's not enough to do everything advocates initially want.
Leading digital medicines company Proteus Digital Health is partnering with Eastern Academic Health Science Network, The Northern Health Science Alliance and Oxford University, Oxford University Hospitals NHS Trust and Oxford Academic Health Science Network to bring digital health technology and global operations and manufacturing to the UK.
The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.
Infants born to HIV-positive mothers had high rates of congenital cytomegalovirus, or CMV. Infants who also were infected before birth by the virus that causes AIDS were especially prone to CMV infection.
› Verified 3 days ago
Dr. Meera Ramayya, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9300 Valley Childrens Pl, Mb23, Madera, CA 93636 Phone: 559-353-6600 Fax: 559-353-6612 | |
Dr. Sudhakar Reddivalam, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9300 Valley Childrens Pl, Madera, CA 93638 Phone: 559-353-5550 Fax: 559-353-5587 | |
Dr. Whitney Lyn Kalin, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9300 Valley Childrens Pl, Madera, CA 93636 Phone: 559-353-5700 Fax: 559-353-5708 | |
John Sanchez, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9300 Valley Childrens Pl, Madera, CA 93638 Phone: 559-353-5068 Fax: 559-353-5426 | |
Dr. Jeffrey Thomas Pietz, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9300 Valley Childrens Pl # Se21, Madera, CA 93636 Phone: 559-353-8769 | |
Saul Jacob, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9300 Valley Childrens Pl # Gw12, Madera, CA 93636 Phone: 559-353-5068 Fax: 559-353-5426 | |
Keenia Tappin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9300 Valley Childrens Pl, Madera, CA 93636 Phone: 559-353-5174 |